Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin

Human Molecular Genetics

Volumn 20, Issue 3, 2011, Pages 436-444

  Yang, Shao H ^a   Chang, Sandy Y ^a   Ren, Shuxun ^a   Wang, Yibin ^a   Andres, Douglas A ^b   Spielmann, H Peter ^b   Fong, Loren G ^a   Young, Stephen G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; NON FARNESYLATED PROGERIN; PROTEIN; SERINE; UNCLASSIFIED DRUG;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BONE ATROPHY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DISEASE SEVERITY; GROWTH RETARDATION; HYPOTHESIS; MALE; MOUSE; NONHUMAN; OSTEOPOROSIS; PHENOTYPE; PRIORITY JOURNAL; PROGERIA; PROTEIN EXPRESSION; PROTEIN PRENYLATION; RIB FRACTURE; SURVIVAL;

AMINO ACID SUBSTITUTION; ANIMALS; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FEMALE; GENE KNOCK-IN TECHNIQUES; IMIDAZOLES; LAMIN TYPE A; MALE; MICE; MUTATION; NUCLEAR PROTEINS; PHENOTYPE; PROGERIA; PROTEIN PRECURSORS; PROTEIN PRENYLATION;

MUS;

EID: 78651095782     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddq490     Document Type: Article

References (45)

1. Eriksson, M., Brown, W.T., Gordon, L.B., Glynn, M.W., Singer, J., Scott, L., Erdos, M.R., Robbins, C.M., Moses, T.Y., Berglund, P. et al. (2003) Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature, 423, 293-298.
2. de Sandre-Giovannoli, A., Bernard, R., Cau, P., Navarro, C., Amiel, J., Boccaccio, I., Lyonnet, S., Stewart, C.L., Munnich, A., Le Merrer, M. et al. (2003) Lamin A truncation in Hutchinson-Gilford progeria. Science, 300, 2055.
3. Worman, H.J. and Bonne, G. (2007) "Laminopathies": a wide spectrum of human diseases. Exp. Cell. Res., 313, 2122-2133.
4. Kudlow, B.A., Kennedy, B.K. and Monnat, R.J. Jr. (2007) Werner and Hutchinson-Gilford progeria syndromes: mechanistic basis of human progeroid diseases. Nat. Rev. Mol. Cell Biol., 8, 394-404.
5. Meta, M., Yang, S.H., Bergo, M.O., Fong, L.G. and Young, S.G. (2006) Protein farnesyltransferase inhibitors and progeria. Trends Mol. Med., 12, 480-487.
6. Young, S.G., Fong, L.G. and Michaelis, S. (2005) Prelamin A, Zmpste24, misshapen cell nuclei, and progeria-new evidence suggesting that protein farnesylation could be important for disease pathogenesis. J. Lipid. Res., 46, 2531-2558.
7. Young, S.G., Meta, M., Yang, S.H. and Fong, L.G. (2006) Prelamin A farnesylation and progeroid syndromes. J. Biol. Chem., 281, 39741-39745.
8. Yang, S.H., Bergo, M.O., Toth, J.I., Qiao, X., Hu, Y., Sandoval, S., Meta, M., Bendale, P., Gelb, M.H., Young, S.G. et al. (2005) Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc. Natl Acad. Sci. USA, 102, 10291-10296.
9. Yang, S.H., Meta, M., Qiao, X., Frost, D., Bauch, J., Coffinier, C., Majumdar, S., Bergo, M.O., Young, S.G. and Fong, L.G. (2006) Treatment with a protein farnesyltransferase inhibitor improves disease phenotypes in mice with a targeted Hutchinson-Gilford progeria syndrome mutation. J. Clin. Invest., 116, 2151-2121.
10. Yang, S.H., Qiao, X., Fong, L.G. and Young, S.G. (2007) Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation. Biochim. Biophys. Acta, 1781, 36-39.
11. Yang, S.H., Chang, S.Y., Andres, D.A., Spielmann, H.P., Young, S.G. and Fong, L.G. (2010) Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria. J. Lipid Res., 51, 400-405.
12. Yang, S.H., Andres, D.A., Spielmann, H.P., Young, S.G. and Fong, L.G. (2008) Progerin elicits disease phenotypes of progeria in mice whether or not it is farnesylated. J. Clin. Invest., 118, 3291-3300.
13. Mounkes, L.C., Burke, B. and Stewart, C.L. (2001) The A-type lamins. Nuclear structural proteins as a focus for muscular dystrophy and cardiovascular diseases. Trends Cardiovasc. Med., 11, 280-285.
14. Muchir, A. and Worman, H.J. (2004) The nuclear envelope and human disease. Physiology (Bethesda), 19, 309-314.
15. Burke, B. and Stewart, C.L. (2002) Life at the edge: the nuclear envelope and human disease. Nat. Rev. Mol. Cell Biol., 3, 575-585.
16. Kirschner, J., Brune, T., Wehnert, M., Denecke, J., Wasner, C., Feuer, A., Marquardt, T., Ketelsen, U., Wieacker, P., Bonnemann, C. et al. (2005) p.S143F mutation in lamin A/C: a new phenotype combining myopathy and progeria. Ann. Neurol., 57, 148-151.
17. Verstraeten, V., Broers, J., Steensel, M.v., Zinn-Justin, S., Ramaekers, F., Steijlen, P., Kamps, M., Kuijpers, H., Merckx, D., Smeets, H. et al. (2006) Compound heterozygosity for mutations in LMNA causes a progeria syndrome without prelamin A accumulation. Hum. Mol. Genet., 15, 2509-2522.
18. Troutman, J.M., Roberts, M.J., Andres, D.A. and Spielmann, H.P. (2005) Tools to analyze protein farnesylation in cells. Bioconjug. Chem., 16, 1209-1217.
19. Dechat, T., Shimi, T., Adam, S., Rusinol, A., Andres, D., Spielmann, H., Sinensky, M. and Goldman, R. (2007) Alterations in mitosis and cell cycle progression caused by a mutant lamin A known to accelerate human aging. Proc. Natl Acad. Sci. USA, 104, 4955-4960.
20. Coffinier, C., Hudon, S.E., Lee, R., Farber, E.A., Nobumori, C., Miner, J.H., Andres, D.A., Spielmann, H.P., Hrycyna, C.A., Fong, L.G. et al. (2008) A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells. J. Biol. Chem., 283, 9797-9804.
21. Davies, B.S., Barnes, R.H. 2nd, Tu, Y., Ren, S., Andres, D.A., Spielmann, H.P., Lammerding, J., Wang, Y., Young, S.G. and Fong, L.G. (2010) An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria. Hum. Mol. Genet., 19, 2692-2694.
22. Vytopil, M., Benedetti, S., Ricci, E., Galluzzi, G., Russo, A.D., Merlini, L., Boriani, G., Gallina, M., Morandi, L., Politano, L. et al. (2003) Mutation analysis of the lamin A/C gene (LMNA) among patients with different cardiomuscular phenotypes. J. Med. Genet., 40, e132.
23. Toth, J.I., Yang, S.H., Qiao, X., Beigneux, A.P., Gelb, M.H., Moulson, C.L., Miner, J.H., Young, S.G. and Fong, L.G. (2005) Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc. Natl Acad. Sci. USA, 102, 12873-12878.
24. Fong, L.G., Ng, J.K., Meta, M., Cote, N., Yang, S.H., Stewart, C.L., Sullivan, T., Burghardt, A., Majumdar, S., Reue, K. et al. (2004) Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice. Proc. Natl Acad. Sci. USA, 101, 18111-18116.
25. Glynn, M.W. and Glover, T.W. (2005) Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum. Mol. Genet., 14, 2959-2969.
26. Capell, B.C., Erdos, M.R., Madigan, J.P., Fiordalisi, J.J., Varga, R., Conneely, K.N., Gordon, L.B., Der, C.J., Cox, A.D. and Collins, F.S. (2005) Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc. Natl Acad. Sci. USA, 102, 12879-12884.
27. Mallampalli, M.P., Huyer, G., Bendale, P., Gelb, M.H. and Michaelis, S. (2005) Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome. Proc. Natl Acad. Sci. USA, 102, 14416-14421.
28. Fong, L., Frost, D., Meta, M., Qiao, X., Yang, S., Coffinier, C. and Young, S. (2006) A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science, 311, 1621-1623.
29. Gordon, L.B., McCarten, K.M., Giobbie-Hurder, A., Machan, J.T., Campbell, S.E., Berns, S.D. and Kieran, M.W. (2007) Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development. Pediatrics, 120, 824-833.
30. Kieran, M.W., Gordon, L. and Kleinman, M. (2007) New approaches to progeria. Pediatrics, 120, 834-841.
31. Denecke, J., Brune, T., Feldhaus, T., Robenek, H., Kranz, C., Auchus, R.J., Agarwal, A.K. and Marquardt, T. (2006) A homozygous ZMPSTE24 null mutation in combination with a heterozygous mutation in the LMNA gene causes Hutchinson-Gilford progeria syndrome (HGPS): insights into the pathophysiology of HGPS. Hum. Mutat., 27, 524-531.
32. Navarro, C.L., Cadinanos, J., De Sandre-Giovannoli, A., Bernard, R., Courrier, S., Boccaccio, I., Boyer, A., Kleijer, W.J., Wagner, A., Giuliano, F. et al. (2005) Loss of ZMPSTE24 (FACE-1) causes autosomal recessive restrictive dermopathy and accumulation of Lamin A precursors. Hum. Mol. Genet., 14, 1503-1513.
33. Moulson, C.L., Go, G., Gardner, J.M., van der Wal, A.C., Smitt, J.H., van Hagen, J.M. and Miner, J.H. (2005) Homozygous and compound heterozygous mutations in ZMPSTE2424 cause the laminopathy restrictive dermopathy. J. Invest. Dermatol., 125, 913-919.
34. Bergo, M.O., Gavino, B., Ross, J., Schmidt, W.K., Hong, C., Kendall, L.V., Mohr, A., Meta, M., Genant, H., Jiang, Y. et al. (2002) Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc. Natl Acad. Sci. USA, 99, 13049-13054.
35. Pendás,A.M., Zhou, Z., Cadiñanos, J., Freije, J.M.P.,Wang, J., Hultenby, K., Astudillo, A., Wernerson, A., Rodríguez, F., Tryggvason, K. et al. (2002) Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat. Genet., 31, 94-99.
36. Leung, G.K., Schmidt, W.K., Bergo, M.O., Gavino, B., Wong, D.H., Tam, A., Ashby, M.N., Michaelis, S. and Young, S.G. (2001) Biochemical studies of Zmpste24-deficient mice. J. Biol. Chem., 276, 29051-29058.
37. Agarwal, A.K., Fryns, J.-P., Auchus, R.J. and Garg, A. (2003) Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Hum. Mol. Genet., 12, 1995-2001.
38. Shackleton, S., Smallwood, D.T., Clayton, P., Wilson, L.C., Agarwal, A.K., Garg, A. and Trembath, R.C. (2005) Compound heterozygous ZMPSTE24 mutations reduce prelamin A processing and result in a severe progeroid phenotype. J. Med. Genet., 42, e36.
39. Lee, R., Chang, S.Y., Trinh, H., Tu, Y., White, A.C., Davies, B.S., Bergo, M.O., Fong, L.G., Lowry, W.E. and Young, S.G. (2010) Genetic studies on the functional relevance of the protein prenyltransferases in skin keratinocytes. Hum. Mol. Genet., 19, 1603-1617.
40. Varela, I., Pereira, S., Ugalde, A.P., Navarro, C.L., Suárez, M.F., Cau, P., Cadiñanos, J., Osorio, F.G., Foray, N., Cobo, J. et al. (2008) Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat. Med., 14, 713-715.
41. Coffinier, C., Jung, H., Li, Z., Nobumori, C., Yun, U., Farber, E., Davies, B., Weinstein, M., Yang, S., Lammerding, J. et al. (2010) Direct synthesis of lamin A, bypassing prelamin a processing, causes misshapen nuclei in fibroblasts but no detectable pathology in mice. J. Biol. Chem., 285, 20818-20826.
42. Kim, E., Ambroziak, P., Otto, J.C., Taylor, B., Ashby, M., Shannon, K., Casey, P.J. and Young, S.G. (1999) Disruption of the mouse Rce1 gene results in defective Ras processing and mislocalization of Ras within cells. J. Biol. Chem., 274, 8383-8390.
43. Dalton, M. and Sinensky, M. (1995) Expression systems for nuclear lamin proteins: farnesylation in assembly of nuclear lamina. Methods Enzymol., 250, 134-148.
44. Fong, L.G., Ng, J.K., Lammerding, J., Vickers, T.A., Meta, M., Cote, N., Gavino, B., Qiao, X., Chang, S.Y., Young, S.R. et al. (2006) Prelamin A and lamin A appear to be dispensable in the nuclear lamina. J. Clin. Invest., 116, 743-752.
45. Yang, S.H., Qiao, X., Fong, L.G. and Young, S.G. (2008) Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation. Biochim. Biophys. Acta, 1781, 36-39.